Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Men and women, aged ≥18 years old at time of enrollment

- Treatment naive subjects with type 2 diabetes mellitus with inadequate glycemic (HbA1c
≥7.0% and ≤9.2% obtained at screening visit) control on diet and exercise alone

- Women must have a negative serum or urine test within 24 hours prior to start of
investigational product

Exclusion Criteria:

- History of ketoacidosis, lactic acidosis or hyperosmolar non-ketonic coma

- Symptoms of poorly controlled diabetes, including but not limited to marked polyuria
and polydipsia with >10% weight loss during last 3 months

- Serum creatinine ≥1.50 mg/dL (133 μmol/L) for male subjects; serum creatinine ≥1.40
mg/dL (124 μmol/L for female subjects)